Advanced Solid Tumors — First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors
Citation(s)
Clinical Study on Evaluating the Safety and Tolerability of Bispecific Antibody MR001 in Patients With Advanced Solid Tumors.